Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.
Andrew T LenisKarissa A WhitingVignesh RavichandranJacob E TallmanSyed M AlamCarissa E ChuManual De Jesus EscanoEmily BochnerAndrew KatimsPeter A ReiszHong TruongTimothy N ClintonLeon TelisShawn DasonVictor A McPhersonMin Yuen TeoSamuel A FuntDavid Henry AggenAlvin C GohTimothy F DonahueEugene K ChaS Machele DonatHarry W HerrGuido DalbagniNikolaus SchultzMichael F BergerDean F BajorinJonathan E RosenbergBernard H BochnerIrina OstrovnayaHikmat A Al-AhmadieDavid B SolitGopakumar V IyerEugene J PietzakPublished in: JCO precision oncology (2024)
Although chemotherapy-resistant bladder cancer generally portends a poor prognosis, patients with organ-confined disease without LVI may be candidates for close observation without adjuvant therapy. The genomic landscape of chemotherapy-resistant tumors is similar to chemotherapy-naïve tumors. Therapeutic opportunities exist for targeted therapies as adjuvant treatment in chemotherapy-resistant disease.